| |||||||
Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse Background Strain C57BL/6 Donor Strain 129S7 via AB1 ES cell line (+Hprt-bm2) Generation N5+1+F1 Donating Investigator The Jackson Laboratory, Description
Male mice homozygous for the Amhtm1Bhr mutation have testes that are fully descended and produce functional sperm. They also develop a uterus which interferes with sperm transfer rendering most infertile. The testes develop Leydig cell hyperplasia. Homozygous females are fertile.Development
The Amhtm1Bhr mutant strain was developed in the laboratory of Dr. Richard Behringer at the University of Texas, MD Anderson Cancer Center. The 129-derived AB-1 ES cell line was used. The C57BL/6J strain was generated by backcrossing mice carrying the Amhtm1Bhr mutation 5 or more times to C57BL/6J inbred mice.
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Strains carrying Amhtm1Bhr allele
002187 B6;129S7-Amhtm1Bhr/J View Strains carrying Amhtm1Bhr (1 strain)
Strains carrying other alleles of Amh
007915 129S.FVB-Tg(Amh-cre)8815Reb/J View Strains carrying other alleles of Amh (1 strain)
Congenic Nomenclature
View Mammalian Phenotype Terms
Mammalian Phenotype Terms
assigned by genotype
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Amhtm1Bhr/Amh+
involves: 129S7/SvEvBrd * C57BL/6
- endocrine/exocrine gland phenotype
- increased ovary weight (MGI Ref ID J:58577)
- the ovarian weight was greater than that of wild-type mice and less than that of homozygous mutant mice
- reproductive system phenotype
- increased ovary weight (MGI Ref ID J:58577)
- the ovarian weight was greater than that of wild-type mice and less than that of homozygous mutant mice
Amhtm1Bhr/Amhtm1Bhr
either: (involves 129P3/J * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
- endocrine/exocrine gland phenotype
- Leydig cell hyperplasia (MGI Ref ID J:21396)
- focal hyperplasia in 27% of males 10 weeks or older
- in spite of the hyperplasia, the cells were functionally normal
- one neoplasm containing multiple foci of leydig cell hyperplasia was detected
- reproductive system phenotype
- *normal* reproductive system phenotype (MGI Ref ID J:21396)
- XX females were fertile and displayed normal uteri containing morphologically normal oviducts
- Leydig cell hyperplasia (MGI Ref ID J:21396)
- focal hyperplasia in 27% of males 10 weeks or older
- in spite of the hyperplasia, the cells were functionally normal
- one neoplasm containing multiple foci of leydig cell hyperplasia was detected
- male pseudohermaphroditism (MGI Ref ID J:21396)
- XY male mice developed hypoplastic female structures derived from the Mullerian duct, namely a uterus, uncoiled oviducts, and a vagina
- uterine horns paralleled the vas deferens and joined to form cervix that opened into a vagina
- the physical association of the uterine horns with the vas deferens caused the horns to be pulled caudally
- XY males displayed normal sized testes that were fully descended and spermatogenesis was unimpaired
- proper differentiation of the Wolffian duct system
- reduced male fertility (MGI Ref ID J:21396)
- 13% of males were able to impregnate wild-type females
- infertility putatively due to a blockage of sperm movement resulting in a diversion from the normal pathway
- secondary sex reversal (MGI Ref ID J:21396)
Amhtm1Bhr/Amhtm1Bhr
involves: 129S7/SvEvBrd * C57BL/6
- endocrine/exocrine gland phenotype
- increased follicle recruitment (MGI Ref ID J:58577)
- increased numbers of preantral and small antral follicles at 25 days and 4 months
- reduced number of primordial follicles observed at 4 months, with further decrease at 13
- increased ovary weight (MGI Ref ID J:58577)
- while the ovaries were morphologically normal at 25 days and 13 months, the weight was 1.8 fold higher than wild-type at 4 months of age
- homeostasis/metabolism phenotype
- suppressed circulating follicle stimulating hormone level (MGI Ref ID J:58577)
- observed in females 4 months of age
- reproductive system phenotype
- increased follicle recruitment (MGI Ref ID J:58577)
- increased numbers of preantral and small antral follicles at 25 days and 4 months
- reduced number of primordial follicles observed at 4 months, with further decrease at 13
- increased ovary weight (MGI Ref ID J:58577)
- while the ovaries were morphologically normal at 25 days and 13 months, the weight was 1.8 fold higher than wild-type at 4 months of age
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:Amhtm1Bhr related
Cancer Research
Increased Tumor Incidence (Gonadal Tumors: Leydig cell tumors)
Developmental Biology Research
Internal/Organ Defects (gonads)
Endocrine Deficiency Research
Gonad Defects
Reproductive Biology Research
Developmental Defects Affecting Gonads
Endocrine Deficiencies Affecting Gonads
Fertility Defects
Gonadal Tumors (Leydig cell hyperplasia)
| Allele Symbol | Amhtm1Bhr | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, Richard R Behringer | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | AMH(-); AMHKO; MIS-KO; delta1 (null); | ||
| Mutation Made By | Richard Behringer, Univ of Texas, MD Anderson Cancer Center | ||
| Strain of Origin | 129S7/SvEvBrd-Hprt1<+> | ||
| ES Cell Line Name | AB1 | ||
| ES Cell Line Strain | 129S7/SvEvBrd-Hprt1<+> | ||
| Gene Symbol and Name | Amh, anti-Mullerian hormone | ||
| Chromosome | 10 | ||
| Gene Common Name(s) | MIF; MIS; Mullerian inhibiting substance; | ||
| Molecular Note | A 0.6 kb genomic fragment containing part of exon 1 and exon 2 was replaced with a neomycin selection cassette. [MGI Ref ID J:21396] | ||
Genotyping Protocols
Amhtm1Bhr, STD PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
Behringer RR; Finegold MJ; Cate RL. 1994. Mullerian-inhibiting substance function during mammalian sexual development. Cell 79(3):415-25. [PubMed: 7954809] [MGI Ref ID J:21396]
Amhtm1Bhr relatedAllard S; Adin P; Gouedard L; di Clemente N; Josso N; Orgebin-Crist MC; Picard JY; Xavier F. 2000. Molecular mechanisms of hormone-mediated Mullerian duct regression: involvement of beta-catenin. Development 127(15):3349-60. [PubMed: 10887090] [MGI Ref ID J:62986]
Arango NA; Lovell-Badge R; Behringer RR. 1999. Targeted mutagenesis of the endogenous mouse Mis gene promoter: in vivo definition of genetic pathways of vertebrate sexual development. Cell 99(4):409-19. [PubMed: 10571183] [MGI Ref ID J:58474]
Durlinger AL; Kramer P; Karels B; de Jong FH; Uilenbroek JT; Grootegoed JA; Themmen AP. 1999. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 140(12):5789-96. [PubMed: 10579345] [MGI Ref ID J:58577]
Jeske YW; Mishina Y; Cohen DR; Behringer RR; Koopman P. 1996. Analysis of the role of Amh and Fra1 in the Sry regulatory pathway. Mol Reprod Dev 44(2):153-8. [PubMed: 9115712] [MGI Ref ID J:33399]
Kobayashi A; Shawlot W; Kania A; Behringer RR. 2004. Requirement of Lim1 for female reproductive tract development. Development 131(3):539-49. [PubMed: 14695376] [MGI Ref ID J:133086]
Mishina Y; Rey R; Finegold MJ; Matzuk MM; Josso N; Cate RL; Behringer RR. 1996. Genetic analysis of the Mullerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes Dev 10(20):2577-87. [PubMed: 8895659] [MGI Ref ID J:36027]
Roberts LM; Visser JA; Ingraham HA. 2002. Involvement of a matrix metalloproteinase in MIS-induced cell death during urogenital development. Development 129(6):1487-96. [PubMed: 11880357] [MGI Ref ID J:74911]
Ross AJ; Tilman C; Yao H; MacLaughlin D; Capel B. 2003. AMH induces mesonephric cell migration in XX gonads. Mol Cell Endocrinol 211(1-2):1-7. [PubMed: 14656469] [MGI Ref ID J:125579]
Visser JA; Durlinger AL; Peters IJ; van den Heuvel ER; Rose UM; Kramer P; de Jong FH; Themmen AP. 2007. Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Mullerian hormone null mice. Endocrinology 148(5):2301-8. [PubMed: 17255205] [MGI Ref ID J:129610]
Wu X; Arumugam R; Baker SP; Lee MM. 2005. Pubertal and adult Leydig cell function in Mullerian inhibiting substance-deficient mice. Endocrinology 146(2):589-95. [PubMed: 15514087] [MGI Ref ID J:105534]
Colony Maintenance
Diet Information LabDiet® 5K52/5K67
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.